Dyne Therapeutics, Inc. (DYN)
NMS · Healthcare · Biotechnology
$18.19
+1.34%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$3.01B
Shares Outstanding
165.3M
Exchange
NMS
Currency
USD
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -115.8M | -113.9M | -116.1M | -125.3M |
| Net Income | -110.9M | -108.0M | -112.0M | -120.9M |
| Diluted EPS | $-0.97 | $-0.76 | $-0.76 | $-0.73 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -171.0M | -242.2M | -343.9M | -468.2M |
| Net Income | -168.1M | -235.9M | -317.4M | -446.2M |
| Diluted EPS | $-3.23 | $-3.95 | $-3.37 | $nan |